首页> 外文OA文献 >Attitudes and behavior of peripheral arterial disease patients toward influencing their physician\u27s prescription of cholesterol-lowering medication
【2h】

Attitudes and behavior of peripheral arterial disease patients toward influencing their physician\u27s prescription of cholesterol-lowering medication

机译:外周动脉疾病患者的态度和行为影响他们的医生降低胆固醇药物的处方

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Among 355 peripheral arterial disease (PAD) patients with low density lipoprotein cholesterol (LDL-C) levels \u3e/= 70 mg/dl, we assessed knowledge regarding optimal LDL levels and the importance of LDL-C-lowering therapy. We also assessed PAD participants\u27 behaviors and attitudes regarding their engagement with their physician in treatment decisions for LDL-C lowering. The average baseline LDL-C level of participants was 103.4 mg/dl +/- 30.7 mg/dl. Seventy-six percent of participants were taking at least one cholesterol-lowering medication. Sixty-six percent were unable to define their optimal LDL-C. Only 47% strongly agreed that their own actions and decisions could reduce their LDL-C. Just 29.8% were aware that patients who request specific medications from their physician were more likely to receive them, and 16% had asked their physician whether they should be taking more cholesterol-lowering medication. These findings suggest that further study is needed to identify effective interventions to educate PAD patients and their physicians about the importance of cholesterol-lowering therapy and to encourage PAD patients to participate with their physician in decisions regarding cholesterol-lowering treatment. Clinical Trial Registration - URL: http://www.clinicaltrials.gov. Unique identifier: NCT00217919.
机译:在355名低密度脂蛋白胆固醇(LDL-C)水平\ u3e / = 70 mg / dl的外周动脉疾病(PAD)患者中,我们评估了关于最佳LDL水平的知识以及降低LDL-C的重要性。我们还评估了PAD参与者与他们的医师参与降低LDL-C的治疗决策有关的行为和态度。参与者的平均基线LDL-C水平为103.4 mg / dl +/- 30.7 mg / dl。 76%的参与者正在服用至少一种降低胆固醇的药物。百分之六十六无法定义其最佳LDL-C。只有47%的人强烈同意他们自己的行动和决定可以减少其LDL-C。只有29.8%的人知道需要医生特别药物治疗的患者更有可能接受这些药物,而有16%的人询问医生是否应该服用更多降低胆固醇的药物。这些发现表明,需要进一步研究来确定有效的干预措施,以教育PAD患者及其医师降低胆固醇治疗的重要性,并鼓励PAD患者与其医师一起参与有关降低胆固醇治疗的决定。临床试验注册-URL:http://www.clinicaltrials.gov。唯一标识符:NCT00217919。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号